Semaxanib

Semaxanib
Clinical data
ATC code	none;
Identifiers
	IUPAC name (3Z)-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one;
CAS Number	194413-58-6 ;
PubChem CID	5329098;
IUPHAR/BPS	5056;
ChemSpider	4486260 ;
UNII	71IA9S35AJ;
ChEBI	CHEBI:91083 ;
ChEMBL	ChEMBL276711 ;
CompTox Dashboard (EPA)	DTXSID801025708 ;
Chemical and physical data
Formula	C15H14N2O
Molar mass	238.290 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C2C(\c1ccccc1N2)=C/c3c(cc([nH]3)C)C;
	InChI InChI=1S/C15H14N2O/c1-9-7-10(2)16-14(9)8-12-11-5-3-4-6-13(11)17-15(12)18/h3-8,16H,1-2H3,(H,17,18)/b12-8- ; Key:WUWDLXZGHZSWQZ-WQLSENKSSA-N ;

Semaxanib (INN, codenamed SU5416) is a tyrosine-kinase inhibitor drug designed by SUGEN as a cancer therapeutic. It is an experimental stage drug, not licensed for use on human patients outside clinical trials. Semaxanib is a potent and selective synthetic inhibitor of the Flk-1/KDR vascular endothelial growth factor (VEGF) receptor tyrosine kinase. It targets the VEGF pathway, and both in vivo and in vitro studies have demonstrated antiangiogenic potential.

Clinical data

ATC code	none
Identifiers
IUPAC name (3Z)-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one
CAS Number	194413-58-6^Y
PubChem CID	5329098
IUPHAR/BPS	5056
ChemSpider	4486260^Y
UNII	71IA9S35AJ
ChEBI	CHEBI:91083^Y
ChEMBL	ChEMBL276711^Y
CompTox Dashboard (EPA)	DTXSID801025708
Chemical and physical data
Formula	C₁₅H₁₄N₂O
Molar mass	238.290 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES O=C2C(\c1ccccc1N2)=C/c3c(cc([nH]3)C)C
InChI InChI=1S/C15H14N2O/c1-9-7-10(2)16-14(9)8-12-11-5-3-4-6-13(11)17-15(12)18/h3-8,16H,1-2H3,(H,17,18)/b12-8-^Y Key:WUWDLXZGHZSWQZ-WQLSENKSSA-N^Y